ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia

Leukemia

Volumn 28, Issue 1, 2014, Pages 182-185

  Zaliova, M ^a,b,d   Zimmermannova, O ^b   Dorge P ^a   Eckert, C ^c   Moricke A ^a   Zimmermann, M ^d   Stuchly, J ^b   Teigler Schlegel, A ^e   Meissner, B ^a   Koehler, R ^f   Bartram, C R ^f   Karawajew, L ^c   Rhein, P ^c   Zuna, J ^b   Schrappe, M ^a   Cario, G ^a   Stanulla, M ^d  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD2 ANTIGEN; MIXED LINEAGE LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER PROGNOSIS; CHILD; CHILDHOOD LEUKEMIA; CLONAL VARIATION; CONTROLLED STUDY; ERG GENE; EVENT FREE SURVIVAL; FEMALE; GENE; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; IKZF1 GENE; LETTER; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLEX POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ANTIGENS, CD2; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IKAROS TRANSCRIPTION FACTOR; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANS-ACTIVATORS;

EID: 84891877413     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.282     Document Type: Letter

References (15)

1. Mullighan CG, Downing JR. Global genomic characterization of acute lymphoblastic leukemia. Semin Hematol 2009; 46: 3-15.
2. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011; 29: 551-565.
3. Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol 2009; 46: 52-63.
4. Loughran SJ, Kruse EA, Hacking DF, de Graaf CA, Hyland CD, Willson TA et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat Immunol 2008; 9: 810-819. (Pubitemid 351859165)
5. Mullighan CG, Miller CBS, Su X, Radtke I, Dalton J, Song G et al. ERG Deletions Define a Novel Subtype of B-Progenitor Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 2007; 110: 691.
6. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133-143. (Pubitemid 41039160)
7. Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS, Bedrick EJ et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010; 116: 4874-4884.
8. Zhang J, Mullighan CG, Harvey RC, Wu G, Chen X, Edmonson M et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011; 118: 3080-3087.
9. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782. (Pubitemid 351552626)
10. Kox C, Zimmermann M, Stanulla M, Leible S, Schrappe M, Ludwig WD et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 2010; 24: 2005-2013.
11. Dö rge P, Meissner B, Zimmermann M, Mö ricke A, Schrauder A, Bourquin JP et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2013; 98: 428-432.
12. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G et al. Longterm results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 2000; 14: 2205-2222. (Pubitemid 32042262)
13. Clappier E, Auclerc MF, Rapion J, Bakkus M, Caye A, Khemiri A et al. ERG intragenic deletion (ERGdel) characterizes an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletion. Leukemia 2013; 28: 70-77.
14. Tsuzuki S, Taguchi O, Seto M. Promotion and maintenance of leukemia by ERG. Blood 2011; 117: 3858-3868.
15. Uckun FM, Gaynon PS, Sensel MG, Steinherz PG, Trigg ME, Heerema NA et al. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J Clin Oncol 1997; 15: 2214-2221. (Pubitemid 27251121)